



NEWS RELEASE

**Osaka Medical and Pharmaceutical University, Fukui Tateami
and Teijin Achieve Primary Endpoint in
Cardiovascular Patch Clinical Trial**

Tokyo, Japan, May 17, 2022 --- [Osaka Medical and Pharmaceutical University](#), [Fukui Tateami Co., Ltd.](#) and [Teijin Limited](#) announced today that they have achieved the primary efficacy endpoint in an ongoing clinical trial of the OFT-G1 (provisional name) patch for cardiovascular surgery. The trial, which began in May 2019 to examine patients ranging from infants to adults suffering from congenital heart diseases, has demonstrated the safety and efficacy of the patch in one-year periods following surgery.



OFT-G1 patch in use (image)



OFT-G1 patch

The three partners now plan to apply for approval and launch the OFT-G1 patch for cardiovascular surgery as quickly as possible in Japan and then other countries worldwide. Simultaneously, they will continue enhancing the product's capacity to contribute to the quality of life of patients with cardiovascular diseases.

The patch is expected to alleviate physical, mental or financial burdens that patients and their families may experience in connection with corrective surgeries. It features a revolutionary design developed with Osaka Medical and Pharmaceutical University's expertise in cardiovascular surgery, Fukui Tateami's pioneering warp-knitting technology and Teijin's advanced polymer-application technology. The patch, which consists of a knitted fabric made with biodegradable and non-biodegradable yarns, is coated with a bio-absorbable cross-linked gelatin. Its biotechnological design is expected to enhance the regeneration of natural tissue in patients and adaptability to growing organs in young patients.

Development was supported by a program launched in 2017 by the Japan Agency for Medical Research and Development (AMED) to facilitate collaboration between medical academia and industry. Also, in April 2018, Japan's Ministry of Health, Labor and Welfare designated the OFT-G1 as a "SAKIGAKE" product qualifying for various incentives to speed up approval for clinical use.

Treatments have been devised to improve the long-term survival of patients who undergo cardiovascular surgery for purposes such as replacing defective heart tissue or enlarging narrowed blood vessels (stenosis). Demands are growing for advanced treatments that are less likely to cause stenosis due to the patient's somatic (physical) growth in areas where patches have been implanted, thereby eliminating needs for follow-up operations to replace patches that have deteriorated or calcified after long-term implantation.

About Osaka Medical and Pharmaceutical University

Osaka Medical and Pharmaceutical University was started in 2021 by integrating the Osaka Medical College founded in 1927, and Osaka University of Pharmaceutical Sciences founded in 1904. Osaka Medical and Pharmaceutical University has three faculties of Medicine, Pharmaceutical Sciences, and Nursing.

URL: <https://www.ompu.ac.jp/>

Press Contact

Section of Promoting Academia-Industry-Government Cooperation

Center for Medical Research & Development

Osaka Medical and Pharmaceutical University

+81 72 684 7141

sangakukan@ompu.ac.jp

About Fukui Tateami Co., Ltd.

Fukui Tateami is a warp knitted fabric manufacturing company located in Fukui, Japan, with 90 employees and more. Our products encompass a wide spectrum of applications, such as fashionable apparel, active sportswear, automotive interiors, industrial materials, household textiles. With over 75 years of extensive experience and advanced technology, Fukui Tateami has entered the medical field. It posted sales of JPY2.8 billion (USD 26 million) and total assets of JPY 2.6 billion (USD 23 million) in the fiscal year ending March 31, 2022.

Please visit <http://www.fukutate.co.jp/en>

Press Contact

General Affairs

Fukui Tateami Co., Ltd.

+81 776 54 3602

info@fukutate.co.jp

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare

equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement “Human Chemistry, Human Solutions”, Teijin aims to be a company that supports the society of the future. The group comprises some 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2022

Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp